Interfering with resistance to smoothened antagonists by inhibition of the PI3K pathway in medulloblastoma. - Wikidata - wikimedia - TriplyDB

Interfering with resistance to smoothened antagonists by inhibition of the PI3K pathway in medulloblastoma.

Interfering with resistance to smoothened antagonists by inhibition of the PI3K pathway in medulloblastoma.

http://www.wikidata.org/entity/Q42282551

about

Voltage-gated potassium channel EAG2 controls mitotic entry and tumor growth in medulloblastoma via regulating cell volume dynamics The crosstalk of mTOR/S6K1 and Hedgehog pathways The PRKCI and SOX2 oncogenes are coamplified and cooperate to activate Hedgehog signaling in lung squamous cell carcinoma Molecular subgroups of medulloblastoma: the current consensus Itraconazole and arsenic trioxide inhibit Hedgehog pathway activation and tumor growth associated with acquired resistance to smoothened antagonists Advances in targeted and immunobased therapies for colorectal cancer in the genomic era Advanced basal cell carcinoma, the hedgehog pathway, and treatment options - role of smoothened inhibitors Targeting the Hedgehog Pathway in Pediatric Medulloblastoma Non-Canonical Hh Signaling in Cancer-Current Understanding and Future Directions The Role of Hedgehog Signaling in Tumor Induced Bone Disease Cooperative integration between HEDGEHOG-GLI signalling and other oncogenic pathways: implications for cancer therapy Basal cell carcinoma - molecular biology and potential new therapies Hedgehog signaling pathway and its targets for treatment in basal cell carcinoma Context-dependent signal integration by the GLI code: the oncogenic load, pathways, modifiers and implications for cancer therapy Hedgehog pathway inhibitor saridegib (IPI-926) increases lifespan in a mouse medulloblastoma model Genome sequencing of SHH medulloblastoma predicts genotype-related response to smoothened inhibition Smoothened variants explain the majority of drug resistance in basal cell carcinoma Vismodegib Exerts Targeted Efficacy Against Recurrent Sonic Hedgehog-Subgroup Medulloblastoma: Results From Phase II Pediatric Brain Tumor Consortium Studies PBTC-025B and PBTC-032.The therapeutic potential of targeting the PI3K pathway in pediatric brain tumors Sonidegib, a novel smoothened inhibitor for the treatment of advanced basal cell carcinoma Molecular pathways: novel approaches for improved therapeutic targeting of Hedgehog signaling in cancer stem cells The phosphoinositide 3-kinase pathway and therapy resistance in cancer Subgroup-specific alternative splicing in medulloblastoma Subgroup-specific structural variation across 1,000 medulloblastoma genomes FBW7 suppression leads to SOX9 stabilization and increased malignancy in medulloblastoma Proteasome inhibition reverses hedgehog inhibitor and taxane resistance in ovarian cancer.Smoothened goes molecular: new pieces in the hedgehog signaling puzzle Combined inhibition of GLI and FLT3 signaling leads to effective anti-leukemic effects in human acute myeloid leukemia.Advanced treatment for basal cell carcinomas.BKM120 induces apoptosis and inhibits tumor growth in medulloblastoma Chemical 'Jekyll and Hyde's: small-molecule inhibitors of developmental signaling pathways Pten loss in Olig2 expressing neural progenitor cells and oligodendrocytes leads to interneuron dysplasia and leukodystrophy.Arhgap36-dependent activation of Gli transcription factors.The dual PI3K/mTOR inhibitor NVP-BEZ235 induces tumor regression in a genetically engineered mouse model of PIK3CA wild-type colorectal cancer.Epigenetic states of cells of origin and tumor evolution drive tumor-initiating cell phenotype and tumor heterogeneity.Genome sequencing of pediatric medulloblastoma links catastrophic DNA rearrangements with TP53 mutations.The evolution of the TOR pathway and its role in cancer.Coordinate activation of Shh and PI3K signaling in PTEN-deficient glioblastoma: new therapeutic opportunities.Epigenetic targeting of Hedgehog pathway transcriptional output through BET bromodomain inhibition.Tackling the cancer stem cells - what challenges do they pose?

P2860

Q24294672-32E5EFE6-B146-48F8-AB10-70BD8472A066 Q24308749-DFA729A4-EF3E-4228-873A-DCE6FD1C111D Q24337113-FE0F6119-BF94-47A4-9513-D5AE1FD7B5BD Q24615271-8E0F84C2-28B1-486D-A522-3109AF04D093 Q24632161-E462626D-DE7A-4738-B37C-BDBFBB9306B3 Q26751344-103B73C0-6CD2-459F-A151-CA6D1029A049 Q26775917-8DCECF16-0D53-471E-A982-CD9F9919556F Q26777997-A73E207E-66C4-496B-8E52-293A86A3E8CE Q26783611-896EC38B-FD8E-4EF4-A052-386AF0648D9F Q26783615-2A0BA013-920D-4572-8032-131D8275CBEF Q26865136-818F9703-CE47-4405-90DE-695775F2392E Q27006913-15494DD3-A5D7-4E27-BFC2-65398277B172 Q27021460-CFAD6A90-1D06-4EFA-A3C7-B3946ACB1A51 Q27027214-20F30A4D-9721-4ABC-B81A-50C3FA5EAA87 Q27851780-BA76E429-2AC9-46CA-8DA1-B7B640FC9056 Q27852966-96780278-32BA-4FF9-9A5E-40EA4AB84AFD Q27853140-0DB7B7F6-FFAD-45D9-BEE5-0F8B5B0334E5 Q27853187-DF52B56A-A989-4210-BB58-092F6017516C Q28070264-0D73C88B-B366-4ADA-AA50-EE3A15DB52D3 Q28078947-CE5466ED-9B2E-448C-8A56-F69B96F6DCCE Q28081405-5F3791A3-C426-43EA-AC13-12799DA64BA5 Q28082811-64A58298-8127-4870-A9A6-55C390E1ECC6 Q28260516-D1EF6A83-CB15-48C7-AB7B-63A8B762715D Q28271811-AE2B744E-962C-4E50-B512-72365B215F0A Q28391884-BEACEB98-AD9D-405B-9AE9-A5F551181F2C Q30410019-7339C354-1FBE-4DCD-9004-AC78C91B2F1E Q33359720-14416A93-553F-4923-9D72-D301522929C8 Q33710062-55C4E48F-66EF-49BF-87AC-9F617936B521 Q33790684-D150720F-A165-4B08-9EBA-0799FBA7AFDB Q33853264-70746A4F-CC64-4797-8E33-2D4A28424AB9 Q33877283-E52BB776-4075-4C86-9228-F72193390074 Q33895438-5C6307FC-FA05-4AB2-BC4C-0A578D945495 Q34002623-198388E1-05C9-41AE-A5F5-21625BB1F7C5 Q34038031-16921DF8-74A1-4272-B135-003610A68858 Q34135305-E2C86504-4D5C-478C-9123-6E8EF36313B5 Q34248736-85422B0E-FAE3-46C5-AD43-5C21C6E96847 Q34318188-936FC88C-2EF9-4B06-AB29-AAF740C88A81 Q34374039-2335E4BF-5C18-4465-B8E1-1F01FEDF2271 Q34426872-6818CB6B-41CF-4F03-9DF9-C81C114848E3 Q34523263-0B34AA8A-6FCA-432C-82D1-2F5A98E02BC8

P2860

Interfering with resistance to smoothened antagonists by inhibition of the PI3K pathway in medulloblastoma.

http://www.wikidata.org/entity/Q42282551

description

2010 nî lūn-bûn

@nan

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

2010年论文

@zh

2010年论文

@zh-cn

name

Interfering with resistance to ...... 3K pathway in medulloblastoma.

@en

Interfering with resistance to ...... 3K pathway in medulloblastoma.

@nl

type

label

Interfering with resistance to ...... 3K pathway in medulloblastoma.

@en

Interfering with resistance to ...... 3K pathway in medulloblastoma.

@nl

prefLabel

Interfering with resistance to ...... 3K pathway in medulloblastoma.

@en

Interfering with resistance to ...... 3K pathway in medulloblastoma.

@nl

P1433

Q42282551-6C9ACC17-EC65-46A9-8D02-522F1FBCB745

P1476

Q42282551-1FB7CEC1-EB6F-405E-8374-5089D7A8D458

P2093

Q42282551-0D970A33-5FCE-47A4-A7BF-8CD2E436356D

Q42282551-2F23B177-0698-4ABF-9C1D-1C136ED5A72E

Q42282551-3CBE1699-B20E-493F-8A1F-3219F0DA611C

Q42282551-3CCA764C-7BD5-4FD7-90B7-72EB6C1F5A77

Q42282551-3F9AA25D-49F3-4762-9C06-F7B406998260

Q42282551-40CB02E8-576F-48B8-9CBC-5C4E92943F13

Q42282551-49C97F31-8F3A-4D2F-8274-B5DC6503D752

Q42282551-4AEF0460-2CE9-4656-8427-0CA3172AF703

Q42282551-5CF0D27F-B0FD-42C1-8E51-DDBC463DF506

Q42282551-608DBCB3-5D35-4E05-917D-39829804A556

P2860

Q42282551-0716F354-BED7-4722-8CE6-4EF3E748BE78

Q42282551-13B07D8E-6744-4022-BB3C-BB693884394B

Q42282551-219356B9-729B-45CA-B8F1-B318B1A58B18

Q42282551-286BC498-4B3C-42AC-976D-DC0F2748079A

Q42282551-2B9D3A0F-B8C2-475B-9FC5-90405599856A

Q42282551-306FC70B-6159-4A39-966C-D114A49FF3B9

Q42282551-38203D4B-4811-46C8-A7E8-5923BA7D0D63

Q42282551-3C5664E6-8F8A-4592-A69A-39D158FED22C

Q42282551-4A2E5FAB-C3BE-4D0F-A7B4-881364B66264

Q42282551-4C4650EB-8218-495C-B101-DAE227361DD3

P304

Q42282551-83ABA982-726C-4674-8BFF-315B5A5F1FF4

P31

Q42282551-37EB1E2B-D04E-4290-8CFA-2A55B85F2C5B

P356

Q42282551-A4B967CC-879D-4D45-BDEA-EE87C24F063D

P407

Q42282551-DF941027-5089-463A-9CEE-B84502B306ED

P433

Q42282551-22608534-E83B-4245-B67F-74F300B135BF

P478

Q42282551-39672BF8-7B21-4D07-AEA7-0128455EA963

P50

Q42282551-D55E7BDF-A24F-4340-84C9-39F538E251FE

P577

Q42282551-532F8DDF-FDF7-4AB5-92DD-89AC5D7EF133

P5875

Q42282551-EEACFEFA-0585-49F7-8507-2384FDE8BADA

P698

Q42282551-FD16E5D8-314F-43B9-8848-9F241BF38B75

P921

Q42282551-D4C6FA47-5A4C-493E-A38D-DB463C07B921

P932

Q42282551-DA8A7DA0-6F3A-4D31-817D-7BC872E55B2D

P356

SCITRANSLMED.3001599

P1433

Science Translational Medicine

P1476

Interfering with resistance to ...... I3K pathway in medulloblastoma

@en

P2093

Anlai Wang

http://www.w3.org/2001/XMLSchema#string

Anthony Vattay

http://www.w3.org/2001/XMLSchema#string

Beatriz Ospina

http://www.w3.org/2001/XMLSchema#string

Carlos García-Echeverría

http://www.w3.org/2001/XMLSchema#string

Christoph Lengauer

http://www.w3.org/2001/XMLSchema#string

D Neil Watkins

http://www.w3.org/2001/XMLSchema#string

Dustin L Anderson

http://www.w3.org/2001/XMLSchema#string

Jing Yuan

http://www.w3.org/2001/XMLSchema#string

John Green

http://www.w3.org/2001/XMLSchema#string

Joseph F Kelleher

http://www.w3.org/2001/XMLSchema#string

P2860

Contribution of polycomb homologues Bmi-1 and Mel-18 to medulloblastoma pathogenesis

Small-molecule modulators of Hedgehog signaling: identification and characterization of Smoothened agonists and antagonists

Smoothened mutation confers resistance to a Hedgehog pathway inhibitor in medulloblastoma.

Multiple recurrent genetic events converge on control of histone lysine methylation in medulloblastoma

More powerful procedures for multiple significance testing

Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity

Hedgehog: functions and mechanisms

Pathway mapping tools for analysis of high content data.

Recent patents for Hedgehog pathway inhibitors for the treatment of malignancy.

Hedgehog signalling in cancer.

P304

51ra70

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1126/SCITRANSLMED.3001599

http://www.w3.org/2001/XMLSchema#string

P407

P433

51

http://www.w3.org/2001/XMLSchema#string

P478

2

http://www.w3.org/2001/XMLSchema#string

P50

P577

2010-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

46820535

http://www.w3.org/2001/XMLSchema#string

P698

20881279

http://www.w3.org/2001/XMLSchema#string

P921

medulloblastoma

P932

3422576

http://www.w3.org/2001/XMLSchema#string